SCHEMBL14014160

SCHEMBL14014160

Cn1c(=O)c(Oc2ccccc2F)cc2cnc(NC3CCOCC3)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 1.00
MAPK8 P45983 7/20 0.85
GAK O14976 1/20 0.85
RPS6KA4 O75676 1/20 0.85
PRKD3 O94806 1/20 0.85
MAP4K4 O95819 1/20 0.85
MAPK1 P28482 1/20 0.85
MAPK9 P45984 1/20 0.85
CSNK1D P48730 1/20 0.85
RPS6KA3 P51812 1/20 0.85
MAPK10 P53779 1/20 0.85
DDR1 Q08345 1/20 0.85
MAPK11 Q15759 1/20 0.85
TAOK1 Q7L7X3 1/20 0.85
COQ8A Q8NI60 1/20 0.85
PRKD2 Q9BZL6 1/20 0.85
STK36 Q9NRP7 1/20 0.85
NLK Q9UBE8 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116114 0.93 MAPK14 (0.87) MAPK14MAPK8GAKRPS6KA4PRKD3
R-1487 SCHEMBL29527296 0.92 MAPK14 (1.00) MAPK14MAPK8GAKRPS6KA4PRKD3
R-1487 SCHEMBL5120612 0.92 MAPK14 (1.00) MAPK14MAPK8GAKRPS6KA4PRKD3
SCHEMBL14014600 0.92 MAPK14 (0.84) MAPK14MAPK8GAKRPS6KA4PRKD3
SCHEMBL14014879 0.92 MAPK14 (0.84) MAPK14MAPK8GAKRPS6KA4PRKD3
R-1487 SCHEMBL20582726 0.91 MAPK14 (0.98) MAPK14MAPK8GAKRPS6KA4PRKD3
R-1487 SCHEMBL31119050 0.91 MAPK14 (0.98) MAPK14MAPK8GAKRPS6KA4PRKD3
SCHEMBL14014738 0.91 MAPK14 (0.83) MAPK14MAPK8GAKRPS6KA4PRKD3
SCHEMBL14014544 0.90 MAPK8 (0.84) MAPK14MAPK8GAKRPS6KA4PRKD3
SCHEMBL5112240 0.89 MAPK8 (0.85) MAPK14MAPK8GAKRPS6KA4PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449581-B2 6-Substituted pyrido-pyrimidines POCHE PALO ALTO LLC (US) 2008-11-11 US disclosed
US-7449581-B2 6-Substituted pyrido-pyrimidines POCHE PALO ALTO LLC (US) 2008-11-11 US disclosed
US-20070135458-A1 6-Substituted pyrido-pyrimidines CHEN JIAN J 2007-06-14 US disclosed
US-20070135458-A1 6-Substituted pyrido-pyrimidines CHEN JIAN J 2007-06-14 US disclosed
US-7169794-B2 6-substituted pyrido-pyrimidines ROCHE PALO ALTO LLC (US) 2007-01-30 US disclosed
US-7169794-B2 6-substituted pyrido-pyrimidines ROCHE PALO ALTO LLC (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135458-A1 6-Substituted pyrido-pyrimidines P2RX6, P2RX1, P2RX7 MAPK14 4250/4885MAPK8 3523/4885GAK 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.